Similar to NFATc2, SOX2 was also upregulated in A549 induced for cisplatin resistance (A549 CR) but on NFATc2 knockdown, SOX2 levels were repressed (Figure 6N), suggesting NFATc2/SOX2 coupling was functionally active in resistant cancer cells. This evidence concerns the gene NFATC2 and cancer.